Latham Group, Inc.

# Signal Note: Driehaus Capital Initiates SWIM Position Driehaus's $13M entry into Latham Group—a pool and spa equipment manufacturer with no drug pipeline—appears misaligned with the firm's biotech mandate and likely reflects a data error or position in the wrong ticker. Verify whether this signals a growth-stage pivot into industrials or represents a reporting anomaly, as SWIM has no clinical development activity or biotech exposure to justify allocation by a specialized growth biotech fund.